Inphi Corporation Announces Second Quarter 2014 Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Inphi Corporation Announces Second Quarter 2014 Results

SANTA CLARA, CA--(Marketwired - Jul 29, 2014) - Inphi Corporation ( NYSE : IPHI ), a leading provider of high-speed mixed signal semiconductor solutions for the communications, data center and computing markets, today announced financial results for its second quarter ended June 30, 2014.

Revenue for the second quarter of 2014 was $33.9 million, up 9% sequentially from $31.2 million reported for the first quarter of 2014. This was up 39% year-over-year compared with $24.3 million reported for the second quarter of 2013. 

Gross margin under U.S. generally accepted accounting principles (GAAP) for the second quarter of 2014 was 63.8% of revenue, compared with 63.5% of revenue for the second quarter of 2013.

GAAP net income for the second quarter of 2014 was $2.6 million, or $0.08 per diluted common share, compared with GAAP net loss of $1.5 million, or ($0.05) per diluted common share, for the second quarter of 2013.

Inphi reports gross margin, net income (loss), and earnings per share in accordance with GAAP and on a non-GAAP basis. A reconciliation of the GAAP to non-GAAP gross margin, net income, and earnings per share, as well as a description of the items excluded from the non-GAAP calculations, is included in the financial statements portion of this news release. 

Gross margin on a non-GAAP basis for both the second quarter of 2014 and 2013 was 64.6% of revenue.

Non-GAAP net income for the second quarter of 2014 was $2.9 million, or $0.09 per diluted common share. This compared with non-GAAP net income of $0.3 million, or $0.01 per diluted common share for the second quarter of 2013.

"We are pleased to report that our revenue grew to more than $33.9 million dollars during the second quarter of 2014 -- a 9% sequential increase, and an almost 40% year-over-year increase," said Ford Tamer, President and CEO of Inphi. "This is the sixth quarter in a row, where we have delivered consistent sequential revenue growth. At the same time, we have driven operating margins from 1% five quarters ago to 11% in Q2 2014, resulting in a nine-fold increase in earnings per share during the period. Equally importantly, we achieved these results while continuing to invest in research and development, effectively innovating award winning solutions for our growing list of customers around the world." 

First Half 2014 Results For the six months ended June 30, 2014, revenue was $65.1 million, compared with $46.9 million for the six months ended June 30, 2013. GAAP net income for the six months ended June 30, 2014 was $1.6 million, or $0.05 per diluted share, on approximately 32.9 million diluted weighted average common shares outstanding. This compared with GAAP net loss of $9.1 million, or ($0.31) per diluted share, on approximately 29.1 million diluted weighted average common shares outstanding for the six months ended June 30, 2013.

Non-GAAP net income for the six months ended June 30, 2014 was $5.8 million, or $0.18 per diluted weighted average common share outstanding, on approximately 32.9 million diluted weighted average common shares outstanding. This compared with non-GAAP net income of $0.4 million for the six months ended June 30, 2013, or $0.01 per diluted weighted average common share outstanding.

Business Outlook The following statements are based on our current expectations for the third quarter of 2014. These statements are forward-looking and actual results may differ materially.

  • Inphi expects revenues to be up 5 % - 9% sequentially in Q3 2014, resulting in a range of $35.6 million to $37.0 million.
  • Non-GAAP gross margin is expected to be approximately 64.5% to 65.5%.
  • Stock-based compensation expense is expected to be in the range of $5.6 million to $5.8 million.
  • GAAP results are expected to be a net loss in a range between $0.2 million to $1.0 million, or ($0.01) - ($0.03) per diluted share, on 31.7 million estimated basic shares outstanding.
  • Non-GAAP net income, excluding stock-based compensation expense, is expected to be in the range of $3.2 million to $3.9 million, or $0.10 - $0.12 per diluted share, on 33.5 million estimated fully diluted shares outstanding.

Quarterly Conference Call Today Inphi plans to hold a conference call at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time today with Ford Tamer, President and Chief Executive Officer, and John Edmunds, Chief Financial Officer, to discuss second quarter 2014 results. 

The call can be accessed by dialing 866-318-8615; international callers should dial 617-399-5134, participant passcode: 74484704. Please dial-in ten minutes prior to the scheduled conference call time. A live and archived webcast of the call will be available on Inphi's website at http://investors.inphi.com for up to 30 days after the call.

About Inphi Inphi Corporation is a leading provider of high-speed analog and mixed signal semiconductor solutions for the communications, data center and computing markets. Inphi's end-to-end data transport platform delivers high signal integrity at leading-edge data speeds, addressing performance and bandwidth bottlenecks in networks, from fiber to memory. Inphi's solutions minimize latency in computing environments and enable the rollout of next-generation communications infrastructure. Inphi's solutions provide a vital interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, enterprise and data center servers, and storage platforms. To learn more about Inphi, visit www.inphi.com .

Cautionary Note Concerning Forward-Looking Statements Statements in the press release and certain matters to be discussed on the second quarter of 2014 conference call regarding Inphi Corporation, which are not historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as outlook, believe, expect, may, will, provide, could, and should, and the negative of these terms or other similar expressions. These statements include statements relating to: our business outlook and current expectations for the third quarter of 2014, including our revenue, gross margin, stock-based compensation expense, operating performance, net income, earnings per share; expectations of our growth; expectations of economic trends and macroeconomic conditions; and benefits of using non-GAAP financial measures. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those anticipated as a result of various factors, including: the Company's ability to sustain profitable operations due to its history of losses and accumulated deficit; dependence on a limited number of customers for a substantial portion of revenue and lack of long-term purchase commitments from our customers; product defects; risk related to intellectual property matters, lengthy sales cycle and competitive selection process; lengthy and expensive qualification processes; ability to develop new or enhanced products in a timely manner; development of the markets that the Company targets; market demand for the Company's products; reliance on third parties to manufacture, assemble and test products; ability to compete; and other risks inherent in fabless semiconductor businesses. In addition, actual results could differ materially due to changes in tax rates or tax benefits available, changes in claims that may or may not be asserted, as well as changes in pending litigation. For a discussion of these and other related risks, please refer to Inphi Corporation's recent SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2013, which are available on the SEC's website at www.sec.gov . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof. Inphi Corporation undertakes no obligation to update forward-looking statements for any reason, except as required by law, even as new information becomes available or other events occur in the future.

Inphi, the Inphi logo and Think fast are registered trademarks of Inphi Corporation. All other trademarks used herein are the property of their respective owners.

   
INPHI CORPORATION  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(in thousands of dollars, except share and per share amounts)  
(Unaudited)  
                       
  Three Months Ended June 30,     Six Months Ended June 30,  
  2014     2013     2014     2013  
Revenue $ 33,922     $ 24,339     $ 65,111     $ 46,923  
Cost of revenue   12,296       8,893       23,359       17,185  
                               
Gross margin   21,626       15,446       41,752       29,738  
                               
Operating expenses:                              
  Research and development   15,729       12,796       29,468       24,394  
  Sales and marketing   4,362       3,706       8,312       7,653  
  General and administrative   3,234       2,842       6,299       5,997  
                               
Total operating expenses   23,325       19,344       44,079       38,044  
                               
Income (loss) from operations   (1,699 )     (3,898 )     (2,327 )     (8,306 )
                               
Other income   172       213       332       426  
                               
Income (loss) before income taxes   (1,527 )     (3,685 )     (1,995 )     (7,880 )
Provision (benefit) for income taxes   (4,161 )     (2,211 )     (3,634 )     1,265  
                               
Net income (loss) $ 2,634     $ (1,474 )   $ 1,639     $ (9,145 )
                               
                               
Earnings per share:                              
    Basic $ 0.08     $ (0.05 )   $ 0.05     $ (0.31 )
    Diluted $ 0.08     $ (0.05 )   $ 0.05     $ (0.31 )
                               
Weighted-average shares used in computing earnings per share:                              
    Basic   31,378,909       29,216,338       31,040,240       29,075,504  
    Diluted   33,013,652       29,216,338       32,905,244       29,075,504  
                               

The following table presents details of stock-based compensation expense included in each functional line item in the consolidated statements of operations above:

                               
  Three Months Ended June 30,     Six Months Ended June 30,  
  2014     2013     2014     2013  
  (in thousands of dollars)  
  (Unaudited)  
Cost of revenue $ 298     $ 281     $ 549     $ 514  
Research and development   2,992       2,256       5,381       4,229  
Sales and marketing   940       753       1,798       1,556  
General and administrative   1,170       1,001       2,178       2,018  
                               
  $ 5,400     $ 4,291     $ 9,906     $ 8,317  
                               
                               
                               
INPHI CORPORATION  
CONSOLIDATED BALANCE SHEETS  
(in thousands of dollars)  
(Unaudited)  
             
    June 30, 2014     December 31, 2013  
Assets                
Current assets:                
  Cash and cash equivalents   $ 33,325     $ 31,667  
  Short-term investments in marketable securities     88,931       90,890  
  Accounts receivable, net     14,418       13,073  
  Inventories     7,428       6,767  
  Other current assets     7,069       3,700  
    Total current assets     151,171       146,097  
                 
Property and equipment, net     25,320       22,460  
Goodwill     5,875       5,875  
Deferred tax charge and other assets     9,621       7,910  
    Total assets   $ 191,987     $ 182,342  
                 
Liabilities and Stockholders' Equity                
                 
Current liabilities:                
  Accounts payable   $ 7,531     $ 7,280  
  Accrued expenses and other current liabilities     6,959       8,118  
  Deferred revenue     1,528       1,686  
                 
    Total current liabilities     16,018       17,084  
                 
Other liabilities     4,677       5,865  
    Total liabilities     20,695       22,949  
                 
Stockholders' equity:                
  Common Stock     32       30  
  Additional paid-in capital     235,184       225,007  
  Accumulated deficit     (64,943 )     (66,582 )
  Accumulated other comprehensive income     1,019       938  
Total stockholders' equity     171,292       159,393  
                 
Total liabilities and stockholders' equity   $ 191,987     $ 182,342  
 
 
 
INPHI CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
(in thousands of dollars, except share and per share amounts)

To supplement the audited financial data presented on a GAAP basis, the Company discloses certain non-GAAP financial measures, which exclude stock-based compensation, abandoned office space costs and deferred tax asset valuation allowance. These non-GAAP financial measures are not in accordance with GAAP. These results should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures. The Company believes that its non-GAAP financial information provides useful information to management and investors regarding financial and business trends relating to its financial condition and results of operations because it excludes charges or benefits that management considers to be outside of the Company's core operating results. The Company believes that the non-GAAP measures of gross margin, net income and earnings per share in combination with the Company's financial results calculated in accordance with GAAP, provide investors with additional perspective and a more meaningful understanding of the Company's ongoing operating performance. In addition, the Company's management uses these non-GAAP measures to review and assess the financial performance of the Company, to determine executive officer incentive compensation and to plan and forecast performance in future periods. The Company's non-GAAP measurements are not prepared in accordance with GAAP, and are not an alternative to GAAP financial information, and may be calculated differently than non-GAAP financial information disclosed by other companies.

                         
INPHI CORPORATION    
RECONCILIATION OF GAAP TO NON-GAAP MEASURES    
(in thousands of dollars, except share and per share amounts)    
(Unaudited)    
                         
  Three Months Ended June 30,     Six Months Ended June 30,    
  2014     2013     2014     2013    
GAAP net income (loss) $ 2,634     $ (1,474 )   $ 1,639     $ (9,145 )  
Adjusting items to GAAP net income (loss):                                
  Operating expenses related to stock-based compensation expense, net of tax effect   4,086   (a)   2,628   (a)   7,299   (a)   5,135   (a)
  Abandoned office costs   -       (43 ) (b)   -       90   (b)
  Valuation allowance and delta in interim period tax allocation from GAAP to non-GAAP   (3,791 ) (c)   (782 ) (c)   (3,110 ) (c)   4,280   (c)
Non-GAAP net income $ 2,929     $ 329     $ 5,828     $ 360    
                                 
Shares used in computing non-GAAP basic earnings per share   31,378,909       29,216,338       31,040,240       29,075,504    
                                 
Shares used in computing non-GAAP diluted earnings per share   33,013,652       30,778,280       32,905,244       30,625,873    
                                 
Non-GAAP earnings per share:                                
    Basic $ 0.09     $ 0.01     $ 0.19     $ 0.01    
    Diluted $ 0.09     $ 0.01     $ 0.18     $ 0.01    
                                 
GAAP gross margin as a % of revenue   63.8 %     63.5 %     64.1 %     63.4 %  
Stock-based compensation:                                
  Cost of revenue   0.8 %     1.1 %     0.9 %     1.1 %  
Adjustment to revenue as a result of warranty claim   -       -       -       -    
Non-GAAP gross margin as a % of revenue   64.6 %     64.6 %     65.0 %     64.5 %  
(a) Reflects the stock-based compensation expense recorded relating to stock-based awards. The Company excludes this item when it evaluates the continuing operational performance of the Company as management believes this GAAP measure is not indicative of its core operating performance.
(b) Reflects the cost of abandoned office space. The Company excludes this item when it evaluates the continuing operational performance of the Company as management believes this GAAP measure is not indicative of its core operating performance.
(c) Reflects the change in valuation allowance and delta in interim period tax allocation from GAAP to non-GAAP related to non-GAAP adjustments. Starting 2014, the Company, prospectively changed its method of calculating income taxes on a non-GAAP basis related to considering $213,000 -- the quarterly amortization of a deferred tax charge on an ARB 51-related intercompany transfer of assets. The deferred tax charge relates to intercompany transfer of intellectual property in 2010 for which taxes were already paid. The Company decided to exclude the amortization from the calculation prospectively as it is strictly non-cash accounting amortization that will never convert into cash tax expense. The change is only made prospectively, therefore, a similar amount remains included in the comparable Q2 2013 non-GAAP tax expense. The Company excludes this item when it evaluates the continuing operational performance of the Company as management believes this GAAP measure is not indicative of its core operating performance.
   
   
   
INPHI CORPORATION  
RECONCILIATION OF GAAP TO NON-GAAP MEASURES -THIRD QUARTER 2014 GUIDANCE  
(in thousands of dollars, except share and per share amounts)  
(Unaudited)  
           
  Three Months Ending September 30, 2014  
  High     Low  
Estimated GAAP net income (loss) $ (200 )   $ (1,000 )
Adjusting items to estimated GAAP net income (loss):              
  Operating expenses related to stock-based compensation expense   5,800       5,600  
  Tax effect of stock-based compensation expense   (1,700 )     (1,400 )
Estimated non-GAAP net income $ 3,900     $ 3,200  
               
Shares used in computing estimated non-GAAP diluted earnings per share   33,500,000       33,500,000  
               
Estimated non-GAAP diluted earnings per share $ 0.12     $ 0.10  
               

Corporate Contact: Kim Markle Inphi 408-217-7329 kmarkle@inphi.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 8

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 3

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 5

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 6

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 9

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 9

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 8

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 3

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 3

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bryan Leon Joins Storm Properties to Elevate Acquisitions Team

Updated Category News Views 381

Storm Properties Welcomes Bryan Leon as New Hire Storm Properties Inc., recognized as a significant player in the development, ownership, and management of a variety of properties, is delighted to announce the addition of Bryan Leon to their team as Land Acquisitions Manager. This appointment comes as part of the company's ongoing strategy to strengthen its position in...

Continue Reading
Revolutionizing Trade Setups with Innovative Scanner Technology

Updated Category News Views 280

Revolutionizing Trade Setups with Innovative Scanner Technology Stock Market Guides is thrilled to introduce significant advancements to its cutting-edge stock scanner technology. The latest update empowers users by showcasing the historical track record of various trade setups it identifies, offering unparalleled insight to traders looking to enhance their market...

Continue Reading
EQT Life Sciences Champions $39 Million Investment in Aerska

Updated Category News Views 101

EQT Life Sciences Champions $39 Million Investment in Aerska Advancing RNA Therapeutics EQT Life Sciences has recently announced a significant milestone: leading a $39 million Series A financing round in Aerska. This funding will be instrumental in pushing forward Aerska’s innovative brain shuttle technology. Designed to optimize the delivery of RNA interference...

Continue Reading
NVIDIA's Anticipated Earnings Report: Key Insights for Investors

Updated Category News Views 160

Understanding NVIDIA's Upcoming Earnings Announcement NVIDIA (NASDAQ: NVDA) is set to release its much-anticipated quarterly earnings report soon. Investors are keen to understand how the company is performing and what guidance it will provide for future quarters. Analysts predict that NVIDIA will announce an earnings per share (EPS) of $0.98, which indicates the level of...

Continue Reading
Innovative Partnership Forged for Enhanced Vehicle Safety

Updated Category News Views 185

Innovative Partnership Forged for Enhanced Vehicle Safety NOVOSENSE Microelectronics, a key player in the semiconductor industry known for its high-performance analog and mixed-signal chips, is joining hands with Continental Automotive Technologies to enhance vehicle safety systems. This collaboration aims to push the envelope in developing automotive-grade sensors that...

Continue Reading